CompletedPhase 2NCT00002598
Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Studying Atypical chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Mark Adam Weiss, MDMemorial Sloan Kettering Cancer Center
- Intervention
- recombinant interferon alfa(biological)
- Enrollment
- 30 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 1994 – 2004
Study locations (1)
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00002598 on ClinicalTrials.govOther trials for Atypical chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07238712Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched DonorSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE1, PHASE2NCT06523556Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic LeukemiaUma Borate
- RECRUITINGPHASE1NCT05549661Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap NeoplasmsMayo Clinic